Benzinga | Oct 19, 2021 06:04AM EDT

Needham Maintains Buy on Biogen, Lowers Price Target to $398

Needham analyst Ami Fadia maintains Biogen (NASDAQ:BIIB) with a Buy and lowers the price target from $400 to $398.